Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

ARIAD to Webcast Conference Call on Fourth Quarter and Year-End 2012 Financial Results

  ARIAD to Webcast Conference Call on Fourth Quarter and Year-End 2012
  Financial Results

Business Wire

CAMBRIDGE, Mass. -- February 5, 2013

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will host a
live webcast of its quarterly conference call at 8:30 a.m. (ET) on Monday,
February 25, 2013. Harvey J. Berger, M.D., chairman and chief executive
officer, will host the call. Senior management will discuss the Company’s
financial results as of December 31, 2012, key corporate objectives and
additional corporate activities. The Company will announce the highlights of
these topics in a press release to be issued before the market opens on
February 25, 2013 prior to the conference call.

The live webcast can be accessed by visiting the investor relations section of
the Company’s website at The call can be accessed
by dialing 866-831-6272 (domestic) or 617-213-8859 (international) five
minutes prior to the start time and providing the pass code 59632303. A replay
of the call will be available on the ARIAD website approximately two hours
after completion of the call and will be archived for three weeks.


ARIAD Pharmaceuticals, Inc. is a global oncology company focused on the
discovery, development and commercialization of medicines to transform the
lives of cancer patients. ARIAD’s first medicine, Iclusig™, is approved in the
U.S. for the treatment of adult patients with chronic, accelerated or blast
phase chronic myeloid leukemia that is resistant or intolerant to prior
tyrosine kinase inhibitor (TKI) therapy or Philadelphia chromosome-positive
acute lymphoblastic leukemia that is resistant or intolerant to prior TKI
therapy. Additional clinical trials of Iclusig in other cancers are ongoing.
ARIAD is also studying AP26113, another molecularly targeted medicine, in
certain forms of lung cancer. For additional information, visit or follow ARIAD on Twitter (@ARIADPharm).


ARIAD Pharmaceuticals, Inc.
For Investors
Kendra Adams, 617-621-2208
For Media
Liza Heapes, 617-621-2315
Sponsored Links
Sponsored Links